Cargando…
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to identify patients with advanced non-small-cell lung cancer (NSCLC) who are most likely to benefit from crizotinib. This study was to evaluate the cost-effectiveness of the ALK tests followed by crizotin...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198972/ https://www.ncbi.nlm.nih.gov/pubmed/30352060 http://dx.doi.org/10.1371/journal.pone.0205827 |